Диссертация (Разработка технологии и состава иммунолипосомальной формы митоксантрона с гуманизированными моноклональными антителами к HER-2 антигену), страница 22

– 2008. – Т. 8. – №. 11. –С. 1641-1648.126. Hauser H., Gains N. Spontaneous vesiculation of phospholipids: a simple and quickmethod of forming unilamellar vesicles //Proceedings of the National Academy of Sciences.– 1982. – Т. 79. – №. 6. – С. 1683-1687.127. Himanshu A., Sitasharan P., Singhai A. K. Liposomes as drug carriers //IJPLS. – 2011.– Т. 2. – №. 7. – С. 945-951.128. Hope M. J. et al.

Production of large unilamellar vesicles by a rapid extrusionprocedure. Characterization of size distribution, trapped volume and ability to maintain amembrane potential //Biochimica et Biophysica Acta (BBA)-Biomembranes. – 1985. – Т.812. – №. 1. – С. 55-65.129. Hospira Healthcare Corporation.

Mitoxantrone Injection, USP Product Monograph.Saint Laurent, Quebec; 13 June 2007.)130. Huang C. H., Mason J. T. Geometric packing constraints in egg phosphatidylcholinevesicles //Proceedings of the National Academy of Sciences. – 1978. – Т. 75. – №. 1. – С.308–310.131. Hui H. W., Robinson J. R., Lee V. H. L.

Design and fabrication of oral controlledrelease drug delivery systems //Controlled Drug Delivery–Fundamentals and Applications.2nd ed. New York: Marcel Dekker Inc. – 1987. – С. 373.132. Immordino M. L. et al. Stealth liposomes: review of the basic science, rationale, andclinical applications, existing and potential //International journal of nanomedicine. – 2006.– Т. 1. – №. 3. – С. 297.133. International Agency for Research on Cancer et al. World cancer report 2014 //Geneva:WHO. – 2014.128134. J.H.

Senior, Fate and behaviour of liposomes in vivo: a review of controlling factors,Crit. Rev. Ther. Drug Carrier Syst. 3 (1987) 123–193.135. Jedrzejczak M. et al. Changes in plasma membrane fluidity of immortal rodent cellsinduced by anticancer drugs doxorubicin, aclarubicin and mitoxantrone //Cell biologyinternational. – 1999. – Т.

23. – №. 7. – С. 497-506.136. Jeijnen J. H.//Analytical profiles of drug substances. – 1988. – Т. 17. – С. 221-258.137. Jesorka A., Orwar O. Liposomes: technologies and analytical applications //Annu. Rev.Anal. Chem. – 2008. – Т. 1. – С. 801-832.138. Kagawa Y., Racker E. Partial Resolution of the Enzymes Catalyzing OxidativePhosphorylation XXV. RECONSTITUTION OF VESICLES CATALYZING 32Pi—ADENOSINE TRIPHOSPHATE EXCHANGE //Journal of Biological Chemistry. – 1971.– Т.

246. – №. 17. – С. 5477-5487.139. Kapuscinski J., Darzynkiewicz Z. Interactions of antitumor agents Ametantrone andMitoxantrone (Novatrone) with double-stranded DNA //Biochemical pharmacology. –1985. – Т. 34. – №. 24. – С. 4203-4213.140. Kasaai M. R. et al. Fragmentation of chitosan by microfluidization process //InnovativeFood Science & Emerging Technologies. – 2003. – Т. 4. – №. 4. – С. 403-413.141. Kharasch E. D., Novak R. F. Mitoxantrone and ametantrone inhibit hydroperoxidedependent initiation and propagation reactions in fatty acid peroxidation //Journal ofBiological Chemistry. – 1985. – Т.

260. – №. 19. – С. 10645-10652.142. Kikuchi H., Yamauchi H. Method for producing liposomes : пат. 4687661 США. –1987.143. Kim H. H. Y., Baianu I. C. Novel liposome microencapsulation techniques for foodapplications //Trends in Food Science & Technology. – 1991. – Т. 2. – С. 55-61.144. Kitayama H. et al. Thermotropic Phase Behavior of Hydrogenated SoybeanPhosphatidylcholine–Cholesterol Binary Liposome Membrane //Chemical andPharmaceutical Bulletin. – 2014. – Т. 62. – №. 1. – С. 58-63.145. Kitayama H. et al. Thermotropic Phase Behavior of Hydrogenated SoybeanPhosphatidylcholine–Cholesterol Binary Liposome Membrane //Chemical andPharmaceutical Bulletin. – 2014. – Т.

62. – №. 1. – С. 58-63.146. Koeller J., Eble M. Mitoxantrone: a novel anthracycline derivative //Clinical pharmacy.– 1988. – Т. 7. – №. 8. – С. 574-581.147. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody ofpredefined specificity //nature. – 1975. – Т. 256. – С.

495-497.148. Konno H. et al. Antitumor effect of a neutralizing antibody to vascular endothelialgrowth factor on liver metastasis of endocrine neoplasm //Japanese journal of cancerresearch. – 1998. – Т. 89. – С. 933-939.149. Kozlowska D. et al. Molecular and magnetic resonance imaging: The value ofimmunoliposomes //Advanced drug delivery reviews. – 2009. – Т. 61. – №. 15. – С. 14021411.150. Kučerka N., Nieh M. P., Katsaras J. Fluid phase lipid areas and bilayer thicknesses ofcommonly used phosphatidylcholines as a function of temperature //Biochimica etBiophysica Acta (BBA)-Biomembranes. – 2011.

– Т. 1808. – №. 11. – С. 2761-2771.151. Lagoueyte N., Paquin P. Effects of microfluidization on the functional properties ofxanthan gum //Food Hydrocolloids. – 1998. – Т. 12. – №. 3. – С. 365-371.152. Lammers T., Hennink W. E., Storm G. Tumour-targeted nanomedicines: principles andpractice //British journal of cancer. – 2008. – Т. 99. – №. 3. – С.

392-397.153. Langmuir I. The constitution and fundamental properties of solids and liquids. II.Liquids. 1 //Journal of the American Chemical Society. – 1917. – Т. 39. – №. 9. – С. 18481906.129154. Lasic D. D. et al. Transmembrane gradient driven phase transitions within vesicles:lessons for drug delivery //Biochimica et Biophysica Acta (BBA)-Biomembranes. – 1995. –Т. 1239.

– №. 2. – С. 145-156.155. Lasic D. D. Liposomes: from physics to applications. – Elsevier Science Ltd, 1993.156. Lasic D. D. The mechanism of vesicle formation //Biochemical Journal. – 1988. – Т.256. – №. 1. – С. 1.157. Leonard R. C. F. et al. Improving the therapeutic index of anthracycline chemotherapy:Focus on liposomal doxorubicin (Myocet™) //The Breast. – 2009.

– Т. 18. – №. 4. – С.218-224.158. Leserman L., Machy P. Ligand targeting of liposomes //Liposomes: From Biophysics toTherapeutics. New York: Marcel Dekker, Inc. – 1987. – С. 157-194.159. Li C. L. et al. Encapsulation of mitoxantrone into pegylated SUVs enhances itsantineoplastic efficacy //European Journal of Pharmaceutics and Biopharmaceutics. – 2008.– Т.

70. – №. 2. – С. 657-665.160. Li Z. et al. Characterization of nebulized liposomal amikacin (Arikace™) as a functionof droplet size //Journal of aerosol medicine and pulmonary drug delivery. – 2008. – Т. 21.– №. 3. – С. 245-254.161. Llu L., Yonetani T. Preparation and characterization of liposome-encapsulatedhaemoglobin by a freeze-thaw method //Journal of microencapsulation.

– 1994. – Т. 11. –№. 4. – С. 409-421.162. Lown J. W. Anthracycline and anthracenedione-based anticancer agents. – Elsevier;Distributors for the US and Canada, Elsevier Science Pub. Co., 1988.163. Lown J. W. et al. Characteristics of the binding of the anticancer agents mitoxantroneand ametantrone and related structures to deoxyribonucleic acids //Biochemistry.

– 1985. –Т. 24. – №. 15. – С. 4028-4035.164. Lown J., Reszka K., Kolodziejczyk P., and Wilson, W. Molecular pharmacology of theanticancer agent mitoxantrone and related structures//Molecular Mechanisms ofCarcinogenic and Antitumor Activity. - 1987.- С. 243-274.165. Lu C. et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP)administered intrapleurally and pathologic response rates in patients with malignant pleuralmesothelioma //Journal of clinical oncology. – 2005.

– Т. 23. – №. 15. – С. 3495-3501.166. Maa Y. F., Hsu C. C. Performance of sonication and microfluidization for liquid–liquidemulsification //Pharmaceutical development and technology. – 1999. – Т. 4. – №. 2. – С.233-240.167. Madden T. D. et al. Protection of large unilamellar vesicles by trehalose duringdehydration: retention of vesicle contents //Biochimica et Biophysica Acta (BBA)Biomembranes. – 1985. – Т.

817. – №. 1. – С. 67-74.168. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature:the key role of tumor-selective macromolecular drug targeting //Advances in enzymeregulation. – 2001. – Т. 41. – №. 1. – С. 189-207.169. Mahdi Jafari S., He Y., Bhandari B. Nano-emulsion production by sonication andmicrofluidization—a comparison //International Journal of Food Properties.

– 2006. – Т. 9.– №. 3. – С. 475-485.170. Mamot C. et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicinloaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalationstudy //The lancet oncology. – 2012.

– Т. 13. – №. 12. – С. 1234-1241.171. Manjappa A. S. et al. Antibody derivatization and conjugation strategies: application inpreparation of stealth immunoliposome to target chemotherapeutics to tumor //Journal ofControlled Release. – 2011. – Т. 150. – №. 1. – С. 2-22.172. Martin F. J. Clinical pharmacology and antitumor efficacy of DOXIL (pegylatedliposomal doxorubicin) //Medical applications of liposomes. – 1998.

– Т. 635. – С. 688.130173. Martin F. J. Pharmaceutical manufacturing of liposomes //Drugs and the pharmaceuticalsciences. – 1990. – Т. 41. – С. 267-316.174. Maruyama K. et al. Possibility of active targeting to tumor tissues with liposomes//Advanced drug delivery reviews. – 1999. – Т. 40. – №. 1. – С. 89-102.175. Maurer-Spurej E. et al. Factors influencing uptake and retention of amino-containingdrugs in large unilamellar vesicles exhibiting transmembrane pH gradients //Biochimica etBiophysica Acta (BBA)-Biomembranes. – 1999. – Т. 1416.

– №. 1. – С. 1-10.176. Mayhew E., Nickolopoulos G., King A. S. An advanced technique for the manufactureof liposomes //Am. Biotech. Lab. – 1985. – Т. 3. – С. 36-41.177. McEvoy G. K. AHFS Drug Information. Bethesda, MD: American Society of HealthSystem Pharmacists. – 2007. – С. 1143-1145.178. Meunier F., Prentice H.